ImmunityBio, Inc. (NASDAQ: IBRX) has entered into a securities purchase agreement to provide funds for working capital and support its ongoing business operations, with multiple institutional investors expecting to deliver gross proceeds of $40 million – and up to $48 million, if fully exercised. The new agreement also includes amendments to the existing warrants issued in February 2023, ensuring the same pricing and terms as the newly issued warrants.
Jefferies LLC is thrilled to be appointed the sole placement agent for the registered direct offering. This is sure to be an exciting opportunity, and we are committed to providing our clients with the best service possible.
Before you invest in this incredible opportunity, make sure you read the prospectus supplement, its accompanying prospectus, and all the other documents that are directly connected to the prospectus supplement and the accompanying prospectus. Doing so will provide you with an in-depth understanding of the offer and will help you make the best possible decision.
About ImmunityBio
ImmunityBio is a biotechnology company pushing the boundaries of therapeutic and preventative medicine. Leveraging our powerful range of immunotherapy and cell therapy platforms, we are developing therapies and vaccines to bolster the natural immunity of our bodies and create long-term defense against cancers and infectious diseases.
Our innovative approaches to cancer treatments have already demonstrated they can potentially reduce or eliminate the need of traditional debilitating high-dose chemotherapy. Join us in our mission for more effective, accessible, and safe treatments and prevention for cancers and infectious diseases.